| 2.24 0 (-0.22%) | 05-29 13:25 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.78 | 1-year : | 3.07 |
| Resists | First : | 2.38 | Second : | 2.63 |
| Pivot price | 2.22  |
|||
| Supports | First : | 1.98 | Second : | 1.64 |
| MAs | MA(5) : | 2.2  |
MA(20) : | 2.3 |
| MA(100) : | 2.5 |
MA(250) : | 2.34 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 40.6 |
D(3) : | 37.4 |
| RSI | RSI(14): 39.7 |
|||
| 52-week | High : | 3.06 | Low : | 1.46 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AYTU ] has closed above bottom band by 45.7%. Bollinger Bands are 17.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.25 - 2.26 | 2.26 - 2.27 |
| Low: | 2.15 - 2.16 | 2.16 - 2.17 |
| Close: | 2.22 - 2.24 | 2.24 - 2.25 |
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Thu, 28 May 2026
AYTU: EXXUA’s launch drives growth as legacy ADHD revenues decline, with strong financial footing - TradingView
Tue, 19 May 2026
Earnings call transcript: Aytu BioPharma Q3 2026 reveals earnings miss - Investing.com
Mon, 18 May 2026
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 - ACCESS Newswire
Mon, 18 May 2026
Pharma firm Aytu BioPharma to present at virtual investor event May 28 - Stock Titan
Sat, 16 May 2026
Analysts Expect Breakeven For Aytu BioPharma, Inc. (NASDAQ:AYTU) Before Long - simplywall.st
Thu, 14 May 2026
Aytu BioPharma, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 11 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 8.9 (%) |
| Held by Institutions | 36.5 (%) |
| Shares Short | 505 (K) |
| Shares Short P.Month | 503 (K) |
| EPS | -4.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.26 |
| Profit Margin | -60.2 % |
| Operating Margin | -32.8 % |
| Return on Assets (ttm) | -3.7 % |
| Return on Equity (ttm) | -97.5 % |
| Qtrly Rev. Growth | -32.8 % |
| Gross Profit (p.s.) | 3.41 |
| Sales Per Share | 5.27 |
| EBITDA (p.s.) | -0.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 2 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.48 |
| PEG Ratio | 0 |
| Price to Book value | 0.67 |
| Price to Sales | 0.41 |
| Price to Cash Flow | 14.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|